Press Releases.
Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia
VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update
Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference
VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update
VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update
Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update
VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper
VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary
VolitionRx Limited Appoints Two New Directors
VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update
New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis
VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
VolitionRx Limited to Present at Conferences in March 2021
VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock
VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts
National Taiwan University Hospital Presents Data on Nu.Q™ Assay Performance at the World Conference on Lung Cancer
VolitionRx Limited Opens its New Manufacturing Facility in Belgium
VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding
VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors
Volition Launches Nu.Q™ Vet Cancer Screening Test in the U.S.
VolitionRx Limited to Present COVID-19 Data at MEDICA 2020
VolitionRx Limited Announces Third Quarter 2020 Financial Results and Business Update
Volition Veterinary Presents Expert Report Ahead of First Product Launch
VolitionRx Limited Schedules Third Quarter 2020 Earnings Conference Call and Business Update
VolitionRx Limited Releases Video of Virtual Capital Markets Day 2020
Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference
VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020
Volition Veterinary Diagnostics Development LLC to Present Product Data Regarding its Nu.Q™ Vet Cancer Screening Test at the 2020 VCS Virtual Annual Conference
VolitionRx Limited Announces Virtual Capital Markets Day 2020
VolitionRx Limited to Present at Conferences in September 2020
VolitionRx Limited Announces Second Quarter 2020 Financial Results and Business Update
VolitionRx Limited Schedules Second Quarter 2020 Earnings Conference Call and Business Update
Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test
VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes
Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference
VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock
VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting
VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update
VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update
Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers
Volition Files Patent for Nu.Q™ COVID-19 Triage Test and Commences Proof of Concept Studies
VolitionRx Limited Releases Annual Corporate Brochure and Video
VolitionRx Limited to Present at Conferences in March 2020
VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update
VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update
Volition Unveils Its Epigenetic Toolbox
VolitionRx Announces Filing of Registration Statements
Volition Develops a New Improved Nu.Q™ Assay Format
VolitionRx Completes Acquisition of Octamer GmbH
VolitionRx Limited Announces Strategic Acquisition
VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test
VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update
Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video
Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC
Nu.Q™ Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas
Volition Appoints Dr. Phillip Barnes to Board of Directors
Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update
Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer
VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update
Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock
VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China
VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update
VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer
VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update
VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report
VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.Q™ Veterinary Diagnostics
VolitionRx Limited Extends Clinical Trial Program in Lung Cancer
VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China
VolitionRx Limited to Present at Conferences in March & April 2019
VolitionRx Limited to Present at Conferences in the U.S. Next Week
VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update
VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update
VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2018 Earnings Conference Call and Business Update
VolitionRx Limited to Expand its Nu.Q™ Trials to Veterinary Diagnostics
VolitionRx Limited Releases Video Featuring Interviews with its Scientific Advisory Board
VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update
Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer
VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study
VolitionRx Announces $9 Million Private Placement
VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update
VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today
Volition Extends Global Reach of its Clinical Trial Program
Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region
VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018
VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update
VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits
VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update
VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock
VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board
VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update
VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update
VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer
VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.
VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone
VolitionRx Limited to Attend Conferences in December
Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies
VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update
VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits
VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding
VolitionRx Announces its European Colorectal Cancer Strategy
VolitionRx to Attend Two Major Conferences in Asia
Volition Granted Four Additional Patents
VolitionRx Limited to Attend Multiple Conferences in September
Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers
VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update
VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update
VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute
Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute
Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress
VolitionRx Limited Corrects an Earlier Announcement
VolitionRx Limited to Present at Multiple Investor Conferences in June
A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q™ assays
VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update
VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test
VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update
Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe
Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory
VolitionRx Appoints David Vanston as Chief Financial Officer
Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States
VolitionRx Limited Announces the Formation of Volition America, Inc.
VolitionRx Limited Celebrates CE Mark Announcement By Ringing Closing Bell at the New York Stock Exchange
VolitionRx Limited to Ring the New York Stock Exchange Closing Bell on Monday, March 13th at 4 pm Eastern Daylight Time
VolitionRx Limited Announces Full Fiscal Year 2016 Financial Results and Business Update
VolitionRx Limited to Present at the 29th Annual ROTH Conference
VolitionRx Limited Schedules Fourth Quarter and Full Year 2016 Earnings Conference Call and Business Update
A Logistics and Pathway Design Study for Volition's CE Marked NuQ(TM) Triage Test has been Commenced in the Capital Region of Denmark
VolitionRx Limited's Triage Test Results Validated in Prospective Trial
VolitionRx Limited to Attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference
VolitionRx Limited to Present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference on February 15, 2017
VolitionRx Limited Strengthens Team with Key Appointment to Drive Sales and Trials in Asia
VolitionRx Limited's Novel Cancer Diagnostic Test Achieves CE Marking as it Prepares for Launch Across Europe
VolitionRx Limited to Present at 9th Annual Biotech Showcase Conference
VolitionRx Limited to Attend Citi 2016 Global Healthcare Conference
VolitionRx Limited to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2016
VolitionRx Limited Announces Third Quarter 2016 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2016 Earnings Conference Call and Business Update
VolitionRx Limited and Hvidovre Hospital Begin Large Prospective Clinical Study
VolitionRx Limited Announces Acquisition of New Belgian Facility and Appointment of COO to Belgian Volition
VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriter
Triage Blood Test Data Presented to Leading International Experts at the World Endoscopy Organization's Colorectal Cancer Screening Committee
Data Presented at ESMO 2016 Demonstrates that VolitionRx Limited's Novel Blood Test for Colorectal Cancer Potentially Reduces the Need for Colonoscopy Referral by 25%
VolitionRx Limited Announces Closing of Public Offering of Common Stock
VolitionRx Limited Announces Pricing of Public Offering of Common Stock
VolitionRx Limited Announces Proposed Public Offering of Common Stock
VolitionRx to Attend Several Conferences in September
Volition's Nu.Q Triage Colorectal Cancer Screening Test Expected to Reduce Colonoscopy Referral by 25 Percent
VolitionRx Schedules Product Launch Update Conference Call for Tuesday, September 6, 2016 at 8:30 am ET
VolitionRx Announces Second Quarter 2016 Financial Results and Business Update
VolitionRx Schedules Second Quarter 2016 Earnings Conference Call and Business Update for Thursday, August 11, 2016 at 8:30am ET
VolitionRx Engages Edison Advisors as Investor Relations Counsel
VolitionRx Granted Fourth U.S. Patent
VolitionRx Appoints Dr. Edward Futcher to Board of Directors
VolitionRx Publishes Study Confirming Stability of Circulating Cell-Free Nucleosomes as Biomarkers for Cancer Diagnostic Blood Tests
VolitionRx to Present at Two Upcoming Conferences in June
VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting
VolitionRx Announces First Quarter 2016 Financial Results and Business Update
VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer
VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET
VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test
VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer
VolitionRx to Participate in 2016 Morgan Stanley Healthcare Insight Series
VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study
VolitionRx Announces CE Marks for Two NuQ® Blood Assays for Detection of Colorectal Cancer
VolitionRx Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
VolitionRx Announces Pricing of Public Offering of Common Stock
VolitionRx Announces Proposed Public Offering of Common Stock
VolitionRx Announces Full Year 2015 Financial Results and Business Update
VolitionRx Schedules Full-Year 2015 Earnings Conference Call and Business Update for Friday, March 11, 2016 at 8:30am ET
Preliminary Data Demonstrates 86% Accuracy in Detecting Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease
VolitionRx Demonstrates 75% Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ® Blood Test
VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection
/C O R R E C T I O N -- VolitionRx Ltd/
VolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK
VolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests
VolitionRx Releases Annual Shareholder Update Letter
VolitionRx Announces Dr. Jason Terrell's Transition to Full-Time Status as Chief Medical Officer and Head of U.S. Operations
VolitionRx Granted Its Third U.S. Patent
VolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study
VolitionRx to Present at LD Micro Conference on December 3 in Los Angeles
VolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy
VolitionRx Granted Its Second U.S. Patent
VolitionRx to Present at Two Conferences in November
VolitionRx Announces Third Quarter 2015 Financial Results and Business Update
VolitionRx Schedules Third Quarter 2015 Earnings Conference Call and Business Update for Wednesday, November 4, 2015 at 8:30am ET
VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study
VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics
VolitionRx Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer
VolitionRx Granted Its First U.S. Patent
VolitionRx Demonstrates NuQ(R) Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial
VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015
VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015
VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer
VolitionRx Announces Second Quarter 2015 Financial Results and Business Update
VolitionRx Schedules Second Quarter 2015 Earnings Conference Call and Business Update for Tuesday, August 11, 2015 at 8:30am ET
VolitionRx to Present at Wedbush PacGrow Healthcare Conference
VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs
VolitionRx CSO Dr. Jake Micallef to Present Scientific Webinar
VolitionRx Expands Scientific Advisory Board
VolitionRx -- placeholder 2015
VolitionRx Partners with Two Market Access Consulting Agencies to Support Market Access of NuQ(R) Colorectal Cancer Tests in Europe
VolitionRx to Present at Two Upcoming Investor Conferences
VolitionRx CEO Cameron Reynolds to Present Informational Webinar
VolitionRx Announces First Quarter 2015 Financial Results and Business Update
VolitionRx Accelerates Clinical Trial with University Hospital Bonn, Germany Evaluating NuQ® Assays in Most Prevalent Cancers
VolitionRx Schedules First Quarter 2015 Earnings Conference Call and Business Update for Tuesday, May 12, 2015 at 8:30 a.m. ET
VolitionRx Initiates Study with Hvidovre Hospital, Denmark, Specifically to Target NuQ(R) Biomarker Panel for Colorectal Polyps
VolitionRx Adds Three New Laboratory Automation Systems to Expedite Sample Analysis for its Large Ongoing Clinical Trials
VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics(R) Technology
VolitionRx Acquires Direct Ownership of Nucleosomics® Technology Patent
VolitionRx Limited Announces Exercise of Over-Allotment Option in Previously Announced Public Offering
VolitionRx Limited Prices Public Offering of Common Stock
VolitionRx Begins First Ovarian Cancer Detection Study
Initial Study Demonstrates that VolitionRx NuQ® Blood Test Has 84% Accuracy in Detecting Early Stage Treatable Pancreatic Cancers
VolitionRx to Initiate Study with University Hospital Bonn to Confirm NuQ® Test Accuracy in Lung Cancer
VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014
VolitionRx Enters Agreement with University of Oxford to Initiate Endometriosis Study
VolitionRx to Present at the SeeThruEquity Conference
VolitionRx Initiates Sponsorship of Two-time Cancer Survivor to Drive Awareness for the Importance of Early Cancer Detection
VolitionRx Presents Further Colorectal Cancer Data at 9th International Conference of Anticancer Research
VolitionRx Announces Prostate Cancer Collaboration with the University of Texas MD Anderson Cancer Center
VolitionRx NuQ(R) Blood Test Detects 84% of Colorectal Cancers; Including Both Early- and Later-stage Cancers
VolitionRx to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
VolitionRx Invests in Laboratory Automation System to Increase Throughput Capacity for Large Clinical Trials
VolitionRx Announces New Chief Financial Officer
VolitionRx -- placeholder 2014
VolitionRx Sells First NuQ® Research Use Only Kits to Active Motif
VolitionRx Appoints Dr. Habib Skaff to Board of Directors
VolitionRx Announces First Published Data in Anticancer Research Journal
VolitionRx Extends Agreement With University Hospital Bonn to Include CE Mark Performance Evaluation
President and CEO of VolitionRx Issues Corporate Update
New VolitionRx Study Data Demonstrates NuQ(R) Assays' High Detection Rate of Prostate Cancer and the Ability to Distinguish Between Prostate and Colorectal Cancer
VolitionRx Completes $3 Million Private Placement
VolitionRx Commences First Large Clinical Trial in Collaboration With Hvidovre Hospital, Denmark
VolitionRx Presents at MicroCapClub Invitational
VolitionRx Announces Engagement of MissionIR Investor Relations Services
VolitionRx Finds Simple Blood Test Detects 85% of Colorectal Cancers and Over 50% of Polyps
VolitionRx to Present at the 6th Annual LD Micro Conference
VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial with Hvidovre Hospital, Denmark
First VolitionRx Study Data Presented at CNAPS, Baltimore
VolitionRx and Active Motif enter into Distribution Agreement for Volition's Research Use Only ELISA Kits
VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant
VolitionRx to use Innova Biosciences' Biotin Technology in its Epigenetic Research Kits
VolitionRx -- placeholder 2013
VolitionRx Embarks on Colorectal Cancer Trial with Hvidovre Hospital, Denmark
Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-Stage Cancer Diagnostic
VolitionRx Files Two Patent Applications
VolitionRx Hires Head of US Operations, Jason Terrell MD
VolitionRx Announces Collaboration with Wales Cancer Bank
Volition Launches NuQ® Epigenetic Immunoassays for Research Use
VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
VolitionRX Issues CEO Letter to Shareholders
VolitionRX Signs Collaboration Agreement With Stefan Holdenrieder of Rheinische Friedrich-Wilhelms-Universitat Bonn Germany
VolitionRx -- placeholder 2012
VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
Pioneering New Science Nucleosomics Advances Blood Based Diagnostics for Cancer
Volition Signs Collaboration Agreement With Abcodia
VolitionRX Limited Intellectual Property Update: New Patent Filed
VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement
Volition Ticker Symbol Changed to VNRX.OB; Name Change to VolitionRX Limited Completed
VolitionRx -- placeholder 2011